DeepMed Research

CATALYSIS SL

🇪🇸Spain

Country: 🇪🇸Spain

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.catalysis.es

Clinical Trials

Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment

Not Applicable

Completed

Conditions: Depression Moderate
Depression Mild
Depression
Post-COVID-19 Syndrome

Interventions: Dietary Supplement: DEPREXIL

First Posted Date: 2024-07-11

Last Posted Date: 2024-07-11

Lead Sponsor: Catalysis SL

Target Recruit Count: 100

Registration Number: NCT06496087

Locations: 🇨🇴
Fundación CR INVESTIGATION INSTITUTE, Bogotá, Bogotá DC, Colombia

Evaluation of Treatment With Viusid in Post-COVID-19 Syndrome

Not Applicable

Completed

Conditions: Inflammation
Post-COVID-19 Syndrome
Fatigue
Dyspnea
Cough
COVID-19

Interventions: Dietary Supplement: Placebo
Dietary Supplement: Viusid Oral Solution

First Posted Date: 2024-05-31

Last Posted Date: 2024-06-03

Lead Sponsor: Catalysis SL

Target Recruit Count: 200

Registration Number: NCT06437210

Locations: 🇨🇴
Fundación CR INVESTIGATION INSTITUTE, Bogotá, Bogotá DC, Colombia

Efficacy and Safety of Blue Cap for the Treatment of Atopic Dermatitis in Children

Phase 3

Completed

Conditions: Atopic Dermatitis and Related Conditions
Atopic Dermatitis Eczema
Atopic Dermatitis
Atopic Dermatitis \(AD\)

Interventions: Other: Blue Cap Foam

First Posted Date: 2024-04-12

Last Posted Date: 2024-04-15

Lead Sponsor: Catalysis SL

Target Recruit Count: 58

Registration Number: NCT06361992

Locations: 🇷🇸
University of Niš Faculty of Medicine, Department of Dermatology and Venereology, University Clinical Center of Niš, Niš, Nišava, Serbia
🇷🇸
City Institute for Skin and Venereal Diseases Belgrade, Belgrade, Serbia
🇷🇸
University of Belgrade Faculty of Medicine, University Clinical Center of Serbia, Belgrade, Serbia

Effect and Safety of Ocoxin Oral Solution on the Quality of Life of Paediatric Patients With Advanced Stage Solid Tumours

Not Applicable

Not yet recruiting

Conditions: Advanced Solid Tumor
Central Nervous System Tumor
Germ Cell Tumor
Sarcoma
Lymphoma, Hodgkin
Pediatric Cancer
Advanced Cancer

Interventions: Dietary Supplement: Ocoxin Oral solution

First Posted Date: 2024-04-12

Last Posted Date: 2024-04-12

Lead Sponsor: Catalysis SL

Target Recruit Count: 40

Registration Number: NCT06363201

Locations: 🇭🇳
Hospital Escuela, Tegucigalpa (Honduras), Tegucigalpa, Francisco Morazan, Honduras

Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)

Phase 4

Recruiting

Conditions: Papilloma Viral Infection
CIN1
LSIL, Low Grade Squamous Intraepithelial Lesion

Interventions: Dietary Supplement: Glizigen
Other: Placebo

First Posted Date: 2023-06-23

Last Posted Date: 2024-02-07

Lead Sponsor: Catalysis SL

Target Recruit Count: 120

Registration Number: NCT05916911

Locations: 🇪🇸
Hospital Ruber Internacional, Madrid, Spain
🇪🇸
Hospital Clinico San Carlos, Madrid, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain

and more 1 locations

The Effectiveness of Spermotrend Food Supplement in the Treatment of Male Infertility

Phase 2

Completed

Conditions: Spermatogenesis and Semen Disorders
Male Infertility
Benign Prostatic Hyperplasia

Interventions: Dietary Supplement: Spermotrend

First Posted Date: 2022-02-03

Last Posted Date: 2023-03-28

Lead Sponsor: Catalysis SL

Target Recruit Count: 150

Registration Number: NCT05222841

Locations: 🇳🇮
Clinica Seniors Managua, Managua, Nicaragua

Evaluation of the Effectiveness of Therapy for Patients With Covid-19 Using Food Supplements Viusid + Asbrip

Not Applicable

Completed

Conditions: Covid19
Viral Infection
SARS-CoV2 Infection
COVID-19 Pneumonia
COVID-19 Respiratory Infection
Infection, Coronavirus
Respiratory Tract Infections

Interventions: Dietary Supplement: Viusid and Asbrip
Drug: COVID-19 Standard Therapy

First Posted Date: 2021-07-28

Last Posted Date: 2022-04-13

Lead Sponsor: Catalysis SL

Target Recruit Count: 80

Registration Number: NCT04980534

Locations: 🇰🇿
City children hospital №1, Astana, Nur-Sultan, Kazakhstan
🇰🇿
JSC "Astana Medical University, Astana, Kazakhstan
🇰🇿
City center for infectious diseases, Astana, Nur-Sultan, Kazakhstan

Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19

Phase 2

Completed

Conditions: Immunomodulator
Respiratory Disease
Covid19
Supportive Care
Antiseptic
Immune System

Interventions: Dietary Supplement: Viusid
Dietary Supplement: Asbrip
Drug: Standard Care

First Posted Date: 2021-01-08

Last Posted Date: 2021-10-21

Lead Sponsor: Catalysis SL

Target Recruit Count: 60

Registration Number: NCT04701502

Locations: 🇧🇬
MBAL, Sv. Mina, Plovdiv, Bulgaria
🇧🇬
MTB Plovdiv, Plovdiv, Bulgaria

Efficacy and Safety of Renalof® in the Removal of Calculi Smaller Than 10 mm Located in the Reno-Ureteral Tract

Phase 2

Completed

Conditions: Ureteral Calculi
Urolithiasis; Lower Urinary Tract
Renal Injury
Renal Stone
Urolithiasis, Calcium Oxalate
Urolithiasis
Kidney Injury
Kidney Calculi
Renal Disease
Ureteral Obstruction

Interventions: Other: Placebo
Dietary Supplement: Renalof

First Posted Date: 2021-01-06

Last Posted Date: 2021-01-06

Lead Sponsor: Catalysis SL

Target Recruit Count: 155

Registration Number: NCT04695951

Locations: 🇳🇮
Clinica Seniors Managua, Managua, Nicaragua

Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19

Phase 2

Completed

Conditions: Covid-19
Sars-CoV2
Diabete Mellitus
Cardiopathy
Renal Disease
Liver Diseases
Pulmonary Disease

Interventions: Dietary Supplement: Viusid and Asbrip

First Posted Date: 2020-05-29

Last Posted Date: 2021-01-08

Lead Sponsor: Catalysis SL

Target Recruit Count: 60

Registration Number: NCT04407182

Locations: 🇪🇨
Hospital de Especialidades Dr. Teodoro Maldonado Carbo, Guayaquil, Ecuador

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy